EA201990952A1 - ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met - Google Patents

ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met

Info

Publication number
EA201990952A1
EA201990952A1 EA201990952A EA201990952A EA201990952A1 EA 201990952 A1 EA201990952 A1 EA 201990952A1 EA 201990952 A EA201990952 A EA 201990952A EA 201990952 A EA201990952 A EA 201990952A EA 201990952 A1 EA201990952 A1 EA 201990952A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
pyridonic
met inhibitor
discloses
met
Prior art date
Application number
EA201990952A
Other languages
English (en)
Other versions
EA038108B1 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62024383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201990952(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of EA201990952A1 publication Critical patent/EA201990952A1/ru
Publication of EA038108B1 publication Critical patent/EA038108B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

В настоящем изобретении раскрыт тип пиридоновых соединений в качестве ингибиторов c-Met, и конкретно раскрыто соединение, как показано в формуле (I), или его фармацевтически приемлемая соль.
EA201990952A 2016-10-27 2017-10-27 Пиридоновое соединение в качестве ингибитора c-met EA038108B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610954377 2016-10-27
PCT/CN2017/107964 WO2018077227A1 (zh) 2016-10-27 2017-10-27 作为c-MET抑制剂的吡啶酮类化合物

Publications (2)

Publication Number Publication Date
EA201990952A1 true EA201990952A1 (ru) 2019-11-29
EA038108B1 EA038108B1 (ru) 2021-07-07

Family

ID=62024383

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990952A EA038108B1 (ru) 2016-10-27 2017-10-27 Пиридоновое соединение в качестве ингибитора c-met

Country Status (28)

Country Link
US (1) US10501443B2 (ru)
EP (1) EP3533787B1 (ru)
JP (1) JP6719679B2 (ru)
KR (1) KR102070748B1 (ru)
CN (1) CN109311812B (ru)
AU (1) AU2017348810B2 (ru)
BR (1) BR112019008415B1 (ru)
CA (1) CA3041164C (ru)
CO (1) CO2019005165A2 (ru)
DK (1) DK3533787T3 (ru)
EA (1) EA038108B1 (ru)
ES (1) ES2835301T3 (ru)
HR (1) HRP20201985T1 (ru)
HU (1) HUE051734T2 (ru)
IL (1) IL266126B (ru)
LT (1) LT3533787T (ru)
MX (1) MX2019004626A (ru)
MY (1) MY189557A (ru)
PE (1) PE20190912A1 (ru)
PH (1) PH12019500875A1 (ru)
PL (1) PL3533787T3 (ru)
PT (1) PT3533787T (ru)
RS (1) RS61126B1 (ru)
SG (1) SG11201903801YA (ru)
SI (1) SI3533787T1 (ru)
UA (1) UA122737C2 (ru)
WO (1) WO2018077227A1 (ru)
ZA (1) ZA201903074B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019260240B2 (en) * 2018-04-26 2023-05-11 Fujian Akeylink Biotechnology Co., Ltd. Crystal form of c-MET inhibitor and salt form thereof and preparation method therefor
EP3919492A4 (en) * 2019-02-01 2022-11-09 Medshine Discovery Inc. TRICYCLIC COMPOUND CONTAINING PYRIMIDINYL GROUP AS C-MET INHIBITOR
WO2022063869A2 (en) 2020-09-24 2022-03-31 Merck Patent Gmbh Compounds for the treatment of viral infections
WO2022253935A1 (en) 2021-06-04 2022-12-08 Merck Patent Gmbh Compounds for the treatment of glioblastoma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001275857A1 (en) * 2000-06-29 2002-01-14 Bristol-Myers Squibb Pharma Company Thrombin or factor xa inhibitors
EP1741703A4 (en) 2004-03-05 2009-11-25 Banyu Pharma Co Ltd PYRIDONE DERIVATIVE
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
WO2013057101A1 (de) 2011-10-17 2013-04-25 Bayer Intellectual Property Gmbh Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer
US20150044211A1 (en) * 2012-03-19 2015-02-12 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
JP2015536910A (ja) * 2012-10-11 2015-12-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗がん活性を有する６−オキソ−１，６−ジヒドロ−ピリダジン誘導体とｍｅｋインヒビターとの組み合わせ
CN106999492B (zh) 2014-12-11 2020-12-11 默克专利股份公司 具有抗癌活性的6-氧代-1,6-二氢-哒嗪衍生物与喹唑啉衍生物的组合

Also Published As

Publication number Publication date
JP6719679B2 (ja) 2020-07-08
KR102070748B1 (ko) 2020-01-29
PE20190912A1 (es) 2019-06-26
PL3533787T3 (pl) 2021-03-08
BR112019008415B1 (pt) 2020-09-29
CN109311812B (zh) 2020-03-17
ES2835301T3 (es) 2021-06-22
JP2019535806A (ja) 2019-12-12
LT3533787T (lt) 2020-11-25
IL266126A (en) 2019-06-30
DK3533787T3 (da) 2020-11-30
RS61126B1 (sr) 2020-12-31
AU2017348810B2 (en) 2020-05-07
WO2018077227A1 (zh) 2018-05-03
US10501443B2 (en) 2019-12-10
HRP20201985T1 (hr) 2021-02-05
AU2017348810A1 (en) 2019-05-23
CA3041164A1 (en) 2018-05-03
CO2019005165A2 (es) 2019-05-31
BR112019008415A2 (pt) 2019-07-09
NZ753020A (en) 2021-08-27
EP3533787A1 (en) 2019-09-04
IL266126B (en) 2020-07-30
EP3533787A4 (en) 2019-11-13
SI3533787T1 (sl) 2021-01-29
SG11201903801YA (en) 2019-05-30
EP3533787B1 (en) 2020-09-30
MY189557A (en) 2022-02-16
ZA201903074B (en) 2020-01-29
PT3533787T (pt) 2020-11-20
PH12019500875A1 (en) 2019-06-17
CN109311812A (zh) 2019-02-05
KR20190058678A (ko) 2019-05-29
EA038108B1 (ru) 2021-07-07
MX2019004626A (es) 2019-11-08
UA122737C2 (uk) 2020-12-28
HUE051734T2 (hu) 2021-03-29
US20190248763A1 (en) 2019-08-15
CA3041164C (en) 2019-12-17

Similar Documents

Publication Publication Date Title
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201791684A1 (ru) Селективные ингибиторы bace1
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201790271A1 (ru) Ингибиторы гликозидазы
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
EA201691421A1 (ru) Гетероарилы и их применение
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201792021A1 (ru) Ингибитор jak
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
PH12019500875A1 (en) Pyridone compound as c-met inhibitor
EA201690911A1 (ru) Соединения диметилбензойной кислоты
EA201592183A1 (ru) Ингибиторы bace
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MX368496B (es) Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp.
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
MY193239A (en) Novel b-lactamase inhibitors
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
DK3790873T3 (da) 1h-indazol-3-carboxamidforbindelser som glycogensynthase-kinase-3-beta-inhibitorer
EA201690908A1 (ru) Пиразолопиримидиновые соединения
EA201690593A1 (ru) Новые соединения мочевины